(See irstructlons); In this competing renewal P01 application, the Administrative Core will continue to provide centralized grant administration, communication processing, and budget management This Core will also serve to amalgamate the investigators, their experimental findings and their ideas, evaluation of research efforts and also to direct the summary efforts toward the Program outcome.
The Specific Aims of the Administrative Core include the following: 1. Provide administrative services to the investigators. This includes the management of project supplies, filing, development of memos, meeting minutes and communications covering all operations, including publications. 2. Organize monthly meetings of the Program Steering Committee to facilitate effective communication and decision making to ensure scientific progress of the Program. 3. Organize an annual External/Internal Scientific Advisory Board meeting. The External and Internal Scientific Advisory Board shall review all experimental findings and clinical outcomes, help prioritize investigations, review the coordination of collaborations, and evaluate concepts that emerge from the studies. 4. Maintain program integration activities. This includes data sharing, rapid publication efforts, and identify and institute other novel activities critical to maintaining and strengthening the integration of the program. 5. Provide overall fiscal review, accounting, and real time budget analyses. This includes reports, verbal communications, reviews and forward-looking projections on expenditures.

Public Health Relevance

The Administrative Core is essential for the functions of the Program as an engine for discovery in the human innate immune system and for translating these basic discoveries into rational immunotherapy for the treatment of human cancers.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-B)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ohio State University
United States
Zip Code
Mani, R; Mao, Y; Frissora, F W et al. (2015) Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia. Leukemia 29:346-55
Stephens, D M; Ruppert, A S; Jones, J A et al. (2014) Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center. Leukemia 28:1365-8
Trikha, Prashant; Carson 3rd, William E (2014) Signaling pathways involved in MDSC regulation. Biochim Biophys Acta 1846:55-65
Riches, John C; Gribben, John G (2014) Immunomodulation and immune reconstitution in chronic lymphocytic leukemia. Semin Hematol 51:228-34
Beckwith, K A; Frissora, F W; Stefanovski, M R et al. (2014) The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model. Leukemia 28:1501-10
Wu, Salene M; Yang, Hae-Chung; Thayer, Julian F et al. (2014) Association of the physiological stress response with depressive symptoms in patients with breast cancer. Psychosom Med 76:252-6
Dubovsky, Jason A; Flynn, Ryan; Du, Jing et al. (2014) Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest 124:4867-76
Mishra, Anjali; Sullivan, Laura; Caligiuri, Michael A (2014) Molecular pathways: interleukin-15 signaling in health and in cancer. Clin Cancer Res 20:2044-50
Kohrt, Holbrook E; Sagiv-Barfi, Idit; Rafiq, Sarwish et al. (2014) Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood 123:1957-60
Jones, Jeffrey A; Byrd, John C (2014) How will B-cell-receptor-targeted therapies change future CLL therapy? Blood 123:1455-60

Showing the most recent 10 out of 186 publications